跳轉至內容
Merck
全部照片(1)

文件

A2736

Sigma-Aldrich

阿那曲唑

≥98% (HPLC)

同義詞:

2;2"-[5-(1H-1;2;4-三唑-1-基甲基)-1, 3-苯] 双(2-甲基丙腈, ICI-D1033, ZD1033, a,a,a′,a′-四甲基-5-(1-H-1,2,4-三唑-1-甲基)-1,3-二乙氰苯, 安美达锭

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C17H19N5
CAS號碼:
分子量::
293.37
分類程式碼代碼:
51111800
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

solid

溶解度

DMSO: 40 mg/mL

起源

AstraZeneca

儲存溫度

room temp

InChI

1S/C17H19N5/c1-16(2,9-18)14-5-13(8-22-12-20-11-21-22)6-15(7-14)17(3,4)10-19/h5-7,11-12H,8H2,1-4H3

InChI 密鑰

YBBLVLTVTVSKRW-UHFFFAOYSA-N

尋找類似的產品? 前往 產品比較指南

應用

阿那曲唑(芳香化酶抑制剂)已被用于:
  • 在DNA片段分析中用作阳性对照
  • 研究其与特级初榨橄榄油及其主要脂肪酸成分(omega-9 OA)对雌激素受体阳性乳腺癌细胞的作用
  • 研究其对多形性胶质母细胞瘤体内模型存活率、细胞增殖和凋亡的影响

生化/生理作用

含有三唑官能团的阿那曲唑能够可逆地与芳香化酶的细胞色素P-450组分结合。这种结合会干扰芳香酶的催化特性,从而导致雌激素的合成受到抑制。
芳香化酶可将肾上腺雄激素转化为雌激素;这种酶活性是绝经后妇女雌激素的主要产生来源。 绝经后妇女雌激素受体阳性乳腺癌的一种治疗方法便是通过抑制芳香化酶。 阿那曲唑是一种非甾体苄基三唑衍生物,可通过竞争性抑制而对芳香化酶进行抑制,并用于治疗雌激素受体阳性的乳腺癌。 该化合物被认为是第三代II型芳香化酶抑制剂,因其与第一代、第二代抑制剂相比,针对其他甾体激素具有更强的选择性和更低的作用(如有)。

特點和優勢

该化合物是受体分类及信号转导手册上核受体(类固醇)页面上的特色化合物。想要浏览手册的其他页面, 请单击此处
该化合物由AstraZeneca开发。要浏览其他药物开发化合物和批准的药物/候选药物列表,单击此处

象形圖

Health hazardExclamation mark

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 4 Oral - Repr. 1B

儲存類別代碼

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析證明 (COA)

輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號,寫有 ‘Lot’或‘Batch’.。

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

P Dubsky et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 24(3), 640-647 (2012-10-05)
In early estrogen receptor (ER)-positive/HER2-negative breast cancer, the decision to administer chemotherapy is largely based on prognostic criteria. The combined molecular/clinical EndoPredict test (EPclin) has been validated to accurately assess prognosis in this population. In this study, the clinical relevance
Yanyan Hong et al.
Steroids, 76(8), 802-806 (2011-03-23)
Aromatase is the rate-limiting enzyme in estrogen biosynthesis. As a cytochrome P450, it utilizes electrons from NADPH-cytochrome P450 reductase (CPR) to produce estrogen from androgen. Estrogen is a key factor in the promotion of hormone-dependent breast cancer growth. Aromatase inhibitors
Novel acylated steroidal glycosides from Caralluma tuberculata induce caspase-dependent apoptosis in cancer cells
Waheed A, et al.
Journal of Ethnopharmacology, 137(3), 1189-1196 (2011)
P I Petkov et al.
SAR and QSAR in environmental research, 20(7-8), 657-678 (2009-12-22)
Cytochrome P450 aromatase is a key steroidogenic enzyme that converts androgens to estrogens in vertebrates. There is much interest in aromatase inhibitors (AIs) both because of their use as pharmaceuticals in the treatment of estrogen-sensitive breast cancers, and because a
Kutlwano R Xulu et al.
International journal of molecular sciences, 22(8) (2021-05-01)
Thromboembolic complications are a leading cause of morbidity and mortality in cancer patients. Cancer patients often present with an increased risk for thrombosis including hypercoagulation, so the application of antiplatelet strategies to oncology warrants further investigation. This study investigated the

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務